预防保障 跨界创新 美年大健康与中国人保财险达成战略合作

2019-07-19 不详 美通社

2019年7月19日,美年大健康产业(集团)有限公司与中国人民财产保险股份有限公司再度强强联合,签订战略合作协议。双方将充分挖掘优势资源,在研发、服务、营销网络方面加强合作,创新健康管理和保险保障服务。 战略合作签约仪式现场 2019年7月19日,美年大健康产业(集团)有限公司与中国人民财产保险股份有限公司再度强强联合,签订战略合作协议。双方将充分挖掘优势资源,在研发、服务、营销网络方面加强合作

2019年7月19日,美年大健康产业(集团)有限公司与中国人民财产保险股份有限公司再度强强联合,签订战略合作协议。双方将充分挖掘优势资源,在研发、服务、营销网络方面加强合作,创新健康管理和保险保障服务。

战略合作签约仪式现场
战略合作签约仪式现场

2019年7月19日,美年大健康产业(集团)有限公司与中国人民财产保险股份有限公司再度强强联合,签订战略合作协议。双方将充分挖掘优势资源,在研发、服务、营销网络方面加强合作,创新健康管理和保险保障服务。

 2018年末,美年大健康与中国人保财险就已在健康管理领域展开了密切的合作。中国人保财险为美年大健康旗下全新健康管理产品“美年好医生”,专项定制了创新健康保险服务 -- 针对体检筛查的检后重大疾病保险、复查费用保险及体检意外保险,多维度保障消费者权益。“美年好医生”产品现已销售并服务超过10万人次,为5万余名消费者完成投保,并为近200位符合理赔条件的消费者完成了保险金赔付。

双方达成战略合作后,美年大健康和中国人保财险将进一步深化保险在美年体系中的应用,继续定制开发专属保险计划,为美年体检客户提供总计逾十亿元保障额度。其中,对于体检结果无异常但在检后一年内确诊重大疾病的消费者,美年大健康将直接提供十万元的重疾关爱津贴,并在后续治疗中为消费者提供最高50万元的费用报销额度,实现保险保障服务的进一步升级。

此外,双方还将共同为彼此的消费者研发更具针对性的健康保险和体检产品,并发挥彼此在人才、技术、渠道网络等方面的综合优势,在健康管理保险服务领域实现更广泛的合作。

美年大健康集团总裁徐可(右三)讲话
美年大健康集团总裁徐可(右三)讲话

美年大健康集团总裁徐可表示:“作为品质与数据共同驱动的健康服务和生命科技公司,美年致力于为消费者提供健康管理全程保障,保险是其中重要的一环。现在我们与中国人保财险的战略合作从单一产品的合作向产品研发、服务互补、渠道合作等多领域延伸,标志着双方将在健康领域为消费者提供更加丰富、创新的服务。”

中国人保财险党委委员、副总裁沈东(左二)讲话
中国人保财险党委委员、副总裁沈东(左二)讲话

中国人保财险党委委员、副总裁沈东表示:“美年大健康是中国专业的健康体检和医疗服务集团。我们非常希望通过此次战略合作,能凭借我们在保险产品研发、保险专业人才以及遍布全国的网络优势,为美年的体检消费者提供更高质量的保险服务。同时,此次合作也将为中国人保财险的消费者带来全新的健康管理增值服务。”

“促进商业保险公司与医疗、体检、护理等机构合作”是《“健康中国2030”规划纲要》中明确提出的要求。美年大健康积极响应国家号召,在健康体检专业领域继续深耕的同时,将进一步加强与知名保险公司的合作,创新提供更加丰富的健康保险服务,满足消费者多样化的健康保障需求,履行“守护每个中国人的生命质量”这一企业使命。

【关于美年大健康】

美年大健康是美年大健康产业控股股份有限公司旗下品牌之一,美年大健康产业控股股份有限公司始创于2004年,是中国专业健康体检和医疗服务集团,总部位于上海,于2018年正式完成中国版图的全覆盖(除港、澳、台地区),实现布局全国600余家专业体检中心,全公司拥有专家团队、医护及管理人员共计70000余名员工。2018年为近3000万人次提供专业健康服务。未来美年健康将设立1000家体检机构,实现年服务8000万人次的战略目标。公司于2015年8月成功在A股上市(SZ:002044),分别于2016年、2017年收购“美兆”、“慈铭”,成为医疗和大健康板块中市值和影响力杰出的上市公司。

【关于中国人保财险】

中国人民财产保险股份有限公司(PICC P&C,以下简称“中国人保财险”)的前身是1949年10月20日成立的中国人民保险公司,是中国人民保险集团股份有限公司(PICC Group,2018年《财富》“世界500 强”第117位)的核心成员和标志性主业,是国内历史悠久、业务规模大、综合实力强的大型国有财产保险公司,保费规模居全球财险市场前列。公司于2003年11月6日在香港联交所主板上市。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2019-07-20 天地飞扬

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1655166, encodeId=f62716551667b, content=<a href='/topic/show?id=2d3de995181' target=_blank style='color:#2F92EE;'>#美年大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79951, encryptionId=2d3de995181, topicName=美年大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36dc24658818, createdName=mnda, createdTime=Thu Mar 19 07:11:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285765, encodeId=baf31285e65cc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478251, encodeId=724614e82516a, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515897, encodeId=e094151589ea9, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Jul 21 14:11:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370017, encodeId=696a3e00174b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jul 20 23:43:16 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369959, encodeId=574c36995903, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Jul 19 23:35:53 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2019-07-19 orangesking

    0

相关资讯

遏制结核病,听听专家怎么说

世界卫生组织提出,到2035年,终止结核病流行,届时要将结核病患病率降到10/10万以下;国家卫生健康委刚刚发布的《遏制结核病行动计划(2019~2022年)》,则在《全国十三五结核病防治规划》基础上提出了具体任务。这些目标和计划的出台,为今后结防工作指出了新方向,我国结核病防治工作也迈入了新时代。日前,由中华医学会结核病学分会等主办的2019年全国结核病学术大会上,多位专家围绕上述主题作了分享。

院士说:癌症是人体“失控”的结果!学会预防衰老 就是在防癌……

癌症是身体“失控”的结果中国工程院院士、西京消化病医院院长樊代明教授认为:“肿瘤”这个过程其实就是我们身体在“抗衰老”的过程。随着时间的推移,人体不可避免地衰老,而我们的身体却在抵抗衰老的进程。身体抵抗衰老的一个重要形式就是细胞的增生、功能加强。可是,一旦身体对细胞增生的过程丧失了控制能力,就会出现细胞无限增生,最终变成“肿瘤”,也就是我们口中的“癌”。这也是为什么我们身边年轻人长肿瘤少,越到老年

Anesth Analg:镁对外科手术患者寒战的预防作用:系统回顾与Meta分析

目前围术期镁的使用对寒战作用的临床试验结果不一,故本研究对围手术期镁预防寒战的效果进行了系统回顾和Meta分析。

NEJM:Galcanezumab预防阵发性丛集性头痛

由此可见,与安慰剂相比,以300 mg剂量皮下给药Galcanezumab,每月一次,可减少初次注射后第1周至第3周阵发性丛集性头痛发作的频率。

NEJM:HIV通用检测及治疗方法可降低30%的感染风险

研究发现,根据当地指导方针,结合预防干预和ART治疗,HIV感染的发生率可降低30%

这类人更容易骨质疏松!不及时更正危害大

很多老人感叹:人老了,骨头变豆腐渣,一摔就折!骨质疏松症是一种退化性疾病,疼痛、驼背、身高降低、骨折是其特征性表现,严重危害中老年人的健康。关于骨质疏松的病因和防治,坊间传闻甚多:吸烟、喝酒、喝茶会导致骨质疏松,女人、老人、瘦子最容易被骨质疏松盯上,晒太阳可防治,骨质疏松了要少运动……这些说法究竟是否正确。